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Abstract 
 
Degradable hydrogels to deliver bioactive proteins represent an emerging platform for 
promoting tissue repair and vascularization in various applications. However, implanting 
these biomaterials requires invasive surgery, which is associated with complications 
such as inflammation, scarring, and infection. To address these shortcomings, we 
applied microfluidics-based polymerization to engineer injectable poly(ethylene glycol) 
microgels of defined size and crosslinked with a protease degradable peptide to allow 
for triggered release of proteins. The release rate of proteins covalently tethered within 
the microgel network was tuned by modifying the ratio of degradable to non-degradable 
crosslinkers, and the released proteins retained full bioactivity. Microgels injected into 
the dorsum of mice were maintained in the subcutaneous space and degraded within 2 
weeks in response to local proteases.  Furthermore, controlled release of VEGF from 
degradable microgels promoted increased vascularization compared to empty microgels 
or bolus injection of VEGF. Collectively, this study motivates the use of microgels as a 
viable method for controlled protein delivery in regenerative medicine applications. 
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1. Introduction 
 
Synthetic hydrogel microparticles (microgels) have broad biomedical applications 
including cell encapsulation and transplantation [1-8], wound healing [9], imaging tools 
[10], and protein and drug delivery [11-15]. Microgels offer additional advantages to the 
attributes of bulk hydrogels for cell and protein delivery, including delivery via catheters 
or injection via small diameter needles, which minimizes complications associated with 
surgery (e.g. trauma, infection, scarring), and preserves native tissue structure without 
in situ gelling considerations that often limit biomedical applications of bulk hydrogels. 
Furthermore, when appropriately sized, microgels conform to the geometry of the 
application site, which facilitates uniform distribution of biomolecules to target sites. 
Importantly, microgels with different characteristics (e.g., different proteins, release 
rates) can be synthesized in separate batches and simple co-delivery of the microgels 
in the desired ratios will result in a “mosaic” formulation resulting in complex or multi-
component materials. 
Of various synthesis routes available to generate synthetic microgels, 
microfluidics-based polymerization is particularly well-suited for preparing microgels 
containing proteins and cells because of the aqueous, cytocompatible nature and 
precise control over particle size of this continuous process [7]. Microgels for protein 
delivery rely on passive diffusion of the protein through a non-degradable microgel 
network, and therefore the release kinetics are solely dictated by protein size and 
microgel mesh size [16]. This inability to modulate protein delivery rate severely hinders 
the application of microgels to regenerative medicine, immunoengineering, and cancer 
therapy. We present a strategy to engineer synthetic microgels with protease-
degradable crosslinks and tunable protein release kinetics. Furthermore, we 
demonstrate that these protease-degradable microgels promote in vivo vascularization 
by controlled release of vascular endothelial growth factor (VEGF) and complete 
degradation of microgels that allows for tissue ingrowth and remodeling. 
2. Materials and Methods 
 
2.1 Microfluidic device fabrication 
PDMS microfluidic flow focusing devices were fabricated using soft lithography 
from silicon and SU8 masters. Devices were plasma treated and then bonded directly to 
glass slides. Microfluidic devices were then heated to 110 °C for 30 minutes to improve 
PDMS-glass sealing. Prior to use, devices were infused with AquapelTM for 30 seconds 
and then purged with nitrogen to render surfaces hydrophobic. 
2.2 4-arm poly(ethylene glycol)-maleimide (PEG-4MAL) microgel generation 
 
PEG-4MAL (20 kDa, Laysan Bio) was dissolved in phosphate-buffered saline 
(PBS) at 5% (w/v) then filtered through a 40 µm cell strainer (Corning). For experiments 
involving the injection of microgels in vivo, microgels were functionalized with 
GRGDSPC (RGD, Genescript). PEG-4MAL was reacted with 2.0 mM RGD for 30 
minutes at 37 °C to create RGD-functionalized macromer. For all other experiments, 
RGD was not used in the formation of microgels. Crosslinker solutions (DTT (Sigma) or 
GCRDVPMSMRGGDRCG (VPM, Genescript) or combinations of both) were prepared 
at predetermined molar concentrations and then adjusted to a pH of 4.5 to slow down 
gelation kinetics in order to prevent the device from clogging. PEG-4MAL and 
crosslinker were then infused into the flow-focusing microfluidic device to form polymer 
droplets. Droplets were formed within an oil solution consisting of light mineral oil 
(Sigma) mixed with 2% SPAN80 (Sigma) and then collected into a 15 mL conical tube 
(Falcon). After formation, microgels were washed in PBS five times by centrifugation to 
remove mineral oil and surfactant. 
2.3 Microgel degradation 
Two hundred microgels were loaded into each well of a 96-well plate. 
Collagenase or PBS was then added to each well and microgels were incubated at 37 
°C for 20 hours. After incubation with protease or PBS, images of each well were 
acquired using a fluorescent microscope and the total number of microgels in the well 
was quantified. 
2.4 Protein release kinetics 
 
Prior to microgel formation, PEG-4MAL was reacted with AlexaFluor488-labeled 
IgG (rat anti-mouse, Thermo Fisher), AlexaFluor555-labeled IgG (rat anti-mouse, 
Thermo Fisher), or VEGF165 homodimer (Thermo Fisher) pre-labeled with NHS-
Dylight488 (Thermo Fisher). All proteins were reacted with PEG-4MAL at 20 µg/mL for 
30 minutes at 37 °C protected from light. After washing, 100 µL of 200 µm diameter 
microgels were added to transwells with 8 µm pore sizes in a 48 well plate (Corning) 
then treated with 3.9 or 39 units/mL of type 1 collagenase in 500 µL of PBS 
(Worthington). The microgels were then maintained in an incubator at 37 °C with gentle 
shaking. At indicated time points, the supernatant was sampled and analyzed on a plate 
reader (Biotek). Images of the microgels were acquired on an inverted microscope 
(Nikon TE 300) with a fluorescent camera (Hamamatsu Orca ER II). 
2.5 VEGF bioactivity assay 
 
We have previously shown that PEGylation of VEGF homodimer primarily results 
in a VEGF molecule conjugated to two PEG-4MAL macromers [17]. To confirm 
PEGylated VEGF maintained bioactivity, human umbilical vein endothelial cells 
(HUVEC, Lonza) were grown in endothelial growth media (EGM-2, Lonza) and 
synchronized in growth factor free basal media (EBM-2, Lonza) with 1% fetal bovine 
serum overnight followed by addition of VEGF, PEG-4MAL conjugated VEGF, PEG-
MAL only, or EGM-2 for 24 h. Cell metabolism was assayed by the CellTiter 96 MTS 
Aqueous Cell Proliferation Assay (Promega). To confirm VEGF released from microgels 
maintained bioactivity, microgels containing VEGF were incubated in MMP-2 (50 nM) 
(R&D Systems) for 30 minutes at 37°C followed by addition of TIMP-1 (50 nM). HUVEC 
were then exposed to released VEGF (100 ng/mL) or soluble VEGF (100 ng/mL) for 24 
h and cell metabolism was assayed. 
2.6 Microgel vascularization 
To track microgel retention in vivo, RGD was conjugated with Dylight750 for IVIS 
imaging or Dylight555 for microscopy imaging then tethered to PEG-4MAL macromer. 
Under protocols approved by Georgia Tech’s Institutional Animal Care and Use 
Committee, C57BL/6J mice (Jackson Labs) were anesthetized with 2.5% isoflurane 
during microgel injection and image acquisition. Backs of mice were shaved, dilapidated 
with NairTM, and sterilized with 70% ethanol. A 1 mL syringe with a 23 gauge 0.5” 
needle was loaded with 100 µL of microgels. The tip of needle was then inserted into 
the subcutaneous space of the dorsum and microgels were slowly injected, taking care 
not to disturb the native tissue structures. A total of 16 mice received two of the 
following microgel formulation chosen for this study: VPM + VEGF, VPM – VEGF, DTT 
+ VEGF, VPM + sVEGF. Experimental groups were designed such that 4 samples were 
used for each group. IVIS Spectrum CT (Perkin Elmer) imaging system was used to 
track microgel position and persistence over time. At 14 day, following injection, 
functional vasculature was labeled by perfusing anesthetized mice with 1.0 mg/mL 
Dylight649-labeled tomato lectin (Vector Labs) via tail vein injection. To wash out 
excess fluorescent lectin, mice were perfused with saline solution. Mice were then 
euthanized with CO2 and the regions of the skin where microgels were injected were 
excised. Microgels and vasculature were imaged using a confocal microscope (Nikon 
Ti-E with Perfect Focus System and C2-Plus Confocal System) and analyzed with 
ImageJ software. 
3. Results 
3.1 Generation of microgels using microfluidics 
To engineer synthetic microgels, we used a PEG-4MAL macromer, which is 
crosslinked into a network via a Michael-type addition reaction with thiols. The PEG-
4MAL platform outperforms other PEG-based polymers in generating structurally 
defined hydrogels with stoichiometric incorporation of ligands and improved crosslinking 
efficiency [17]. In addition, PEG-4MAL exhibits minimal local and systemic inflammation 
and toxicity and is rapidly excreted in the urine [18], important criteria for in vivo 
applications. We designed a microfluidic flow focusing device to produce droplets of 
PEG-4MAL and crosslinker (Fig. 1a). Three independent flow inlets (PEG-4MAL, 
crosslinker, and mineral oil containing SPAN80 surfactant) were used to produce 
droplets. After the PEG-4MAL and crosslinker flow streams merge, the solution is 
focused into an oil-covered droplet where it crosslinks and is then collected at the outlet 
(Video S1, Supporting Information). Microgels of defined diameters with 
homogeneous size distribution can be simply produced by changing the inlet flow rates 
and nozzle size (Fig. 1b,c). To generate protease-degradable microgels, we used the 
crosslinking peptide GCRDVPMSMRGGDRCG (VPM), which is rapidly cleaved by 
matrix metalloproteinase (MMP)-1 and MMP-2 proteases [19]. To confirm protease-
dependent degradation, we first reacted PEG-4MAL with AlexaFluor488-labeled IgG 
(AF488-IgG) to form an AF488-IgG-functionalized macromer and then generated 200 
µm diameter microgels crosslinked with VPM or dithiothreitol (DTT). Microgels were 
incubated in type 1 collagenase at 39 units/mL or 3.9 units/mL in buffer solution and 
imaged on a fluorescence microscope (Fig. 1d). After 20 hours, 100% of the VPM-
crosslinked microgels in 39 units/mL collagenase degraded whereas only 25% of VPM-
crosslinked microgels in 3.9 units/mL collagenase degraded (Fig. 1e). The DTT-
crosslinked microgels did not degrade in the presence of the protease. The degradation 
of VPM-crosslinked microgels was dependent on the concentration of collagenase used 
(Fig. S1, Supporting Information). These results show that VPM-crosslinked 
microgels are degradable by proteases in a concentration-dependent fashion. 
3.2 Tuning microgel release kinetics 
In order to engineer microgels with tunable sensitivity to proteases, and therefore 
tunable release kinetics, we prepared microgels that were crosslinked with varying VPM 
to DTT molar ratios. Fluorescent IgG-loaded microgels were incubated in the presence 
of proteases, the supernatant was sampled at indicated intervals, and fluorescent signal 
was measured. As expected, protein released most quickly from microgels that were 
crosslinked exclusively with protease-sensitive VPM crosslinker, while microgels 
crosslinked with protease-insensitive DTT did not release significant protein after one 
hour in protease, suggesting that the ~20% protein release observed resulted from 
passive diffusion of untethered protein (Fig. 2a). By varying the crosslinker ratio of 
MMP-sensitive VPM to protease-insensitive DTT, the degradation rate of capsules in 
collagenase can be controlled, and therefore the release rate of encapsulated protein 
can be controlled. Protein release in all groups had plateaued after 3 days, suggesting 
that remaining crosslinks were protease-insensitive. Importantly, microgels incubated in 
the absence of protease did not undergo degradation for any crosslinker formulation 
tested, as evidenced by minimal protein release over 80 hours (Fig. 2b). These results 
demonstrate that the degradation and release rate of proteins encapsulated within 
microgels can be engineered. Furthermore, mixtures of different microgels, in this case 
protease-degradable and non-degradable, can be prepared in order to co-deliver 
bioactive molecules with different release rates (Video S2, Fig. S2, Supporting 
Information). 
3.3 In vitro VEGF release kinetics 
An important application for hydrogels is delivery of VEGF protein to promote 
vascularization [20]. We generated VEGF-containing microgels that degrade in the 
presence of protease to explore the application of the microgel delivery platform in 
regenerative medicine. Consistent with our previous observations [18], covalently 
tethering of VEGF to PEG-4MAL through its free cysteine does not affect its bioactivity 
(Fig. S3, Supporting Information). To measure the release kinetics, VEGF was 
labeled with a fluorescent dye and then reacted with PEG-4MAL. The microfluidic 
focusing device was then used to generate 200 µm diameter VPM- or DTT-crosslinked 
microgels (Fig. 3a). VEGF was released for VPM-crosslinked microgels incubated in 
protease, whereas minimal VEGF release occurred over 3 days from DTT-crosslinked 
microgels incubated in protease as well as from VPM-crosslinked microgels incubated 
in saline (Fig. 3b). In a separate set of experiments, unlabeled VEGF was released 
from VPM crosslinked microgels by incubating microgels in MMP-2. Upon complete 
microgel degradation, VEGF was incubated in TIMP-1 in order to inhibit MMP-2 activity. 
VEGF released from the microgels exhibited similar bioactivity levels compared to 
soluble VEGF (Fig 3c). These results confirm protease-dependent release of bioactive 
VEGF from VPM-crosslinked microgels, consistent with observations seen in IgG-
loaded microgels. Notably, the release kinetics were similar to that observed for AF488-
IgG-containing microgels, indicating release kinetics independent of protein size. 
 
3.4 Microgel injection and vascularization in vivo 
To examine the ability of VEGF-releasing microgels to promote vascularization in 
vivo, we injected different microgel formulations in the subcutaneous space in the 
dorsum of mice and measured retention of VEGF and functional vascular ingrowth at 
the site of injection (Fig. 4). Microgel suspensions were simply injected using a standard 
tuberculin syringe with no incision required, and none of the time constraints due to 
crosslinking kinetics that accompany injectable bulk gels. The simplicity of microgel 
injection lends itself to clinical applications where more complex schemes could 
produce heterogeneous material properties (due to inadequate mixing) or more trauma 
at the implant site (due to incision), especially in non-expert hands. In order to track 
microgels and promote tissue repair at the injection site, microgels were covalently 
functionalized with 2.0 mM of the fluorescently labeled adhesive peptide GRGDSPC 
(‘RGD’) by co-incubation of labeled RGD and PEG-4MAL before microgel generation. 
Using an intravital imaging system (IVIS), we monitored the position and fluorescence 
intensity of injected microgels over 14 days in vivo (Fig. 4a). The fluorescent signal 
decreased exponentially over time for the VPM-crosslinked microgels (half-life = 1.3 
days). In contrast, the signal from DTT-crosslinked gels decreased initially but stabilized 
to ~80% of the original signal after day 1 and remained relatively unchanged thereafter. 
(Fig. 4b). This result indicates that VPM-crosslinked microgels degrade in a well-
defined pattern in vivo, while DTT crosslinked microgels do not degrade significantly 
over 14 days. At day 14, the circulatory system of the mice was perfused with 
fluorescently labeled lectin to stain functional vasculature. Confocal images of explanted 
skin regions where microgels were injected show significant increases in the number of 
blood vessels for VEGF-encapsulated VPM-crosslinked microgels compared to empty 
(no VEGF) VPM-crosslinked microgels and to DTT-crosslinked gels loaded with VEGF 
(Fig. 4c,d). Importantly, a bolus of soluble VEGF (sVEGF) co-delivered with empty 
VPM-crosslinked microgels resulted in minimal vascularization, indicating that controlled 
release of VEGF at the treatment site is required to achieve robust vascularization. 
Degradation of VPM-crosslinked microgels promoted host tissue ingrowth, while DTT-
crosslinked microgels were still present at the injection site and prevented tissue 
ingrowth and remodeling (Fig. 4c). These results demonstrate that controlled VEGF 
delivery from protease-degradable microgels promotes robust vascularization and 
tissue remodeling in vivo. 
  
4. Discussion 
Implantation of devices via surgical incisions is often associated with 
complications such as inflammation, infection, trauma, and scarring. Injectable 
biomaterials mitigate these complications and are thus an attractive means for cell and 
drug delivery applications. Here, we present an injectable microgel platform to deliver 
VEGF and promote vascularization. Mice that received degradable microgels releasing 
VEGF exhibited increased vessel formation compared to mice that received empty 
microgels or a bolus injection of VEGF. We attribute this increase in vascularization to 
1) sustained release of VEGF from the microgels, and 2) host cell binding to RGD within 
microgels that provide a scaffold for tissue ingrowth and vascularization. Previous 
reports have shown that sustained release of VEGF combined with a cell-adhesive 
biomaterial scaffold are critical driving factors for improved vascularization [21-23].  
However, the need for invasive surgery to implant bulk, pre-formed devices limits the 
translation of these tools to the clinic. In situ gelation offers a solution for noninvasive 
delivery of biomaterials, though the choice of polymer and crosslinker is often limited by 
physiological conditions that affect gelling such as temperature, pH, and the presence of 
ions [24]. Our results support a microgel-based drug delivery system as an effective 
method for delivering VEGF and potentially other bioactive molecules. 
In a previous report, we utilized a microfluidic device to generate non-degradable 
PEG-4MAL microgels crosslinked in a DTT/oil emulsion [6]. This microfluidic device, 
however, could not produce microgels crosslinked with peptides due to the limited 
solubility of these peptides in oil. We therefore designed a unique microfluidic device to 
generate protease-degradable microgels by reacting PEG-4MAL with VPM. This new 
microfluidic device brings together streams of PEG-4MAL macromer and VPM and the 
mixture is pinched off into a droplet by an oil stream. The new device incorporates a 
serpentine channel which is necessary for allowing sufficient crosslinking of the 
microgels before collection into a conical tube.  We demonstrate precise control over 
microgel size using the PDMS based microfluidic flow focusing device. For 
subcutaneous injections, relatively large diameter particles (~200 µm) and needles did 
not significantly damage native structures. For more delicate procedures which would 
require a smaller diameter needle, smaller diameter microgels (<50 µm) would be 
preferable. 
We demonstrate protease-dependent degradation of these microgels to release 
the incorporated IgG or VEGF. We also show control over the in vitro degradation rate 
of the microgels via tuning the ratio of protease-degradable (VPM) to non-degradable 
(DTT) crosslinker. In addition to the VPM peptide used in this study, other protease-
cleavable peptides with faster or slower degradation rates could be employed as gel 
crosslinkers in order to more precisely control the degradation and protein release 
kinetics [19]. In this way, the release kinetics of proteins from the microgels are 
dependent on local cellular demand rather than release initiated by hydrolysis or other 
chemical stimuli. Microgels labeled with a near infrared dye were used to track microgel 
degradation in vivo. VPM-crosslinked microgels exhibited an exponential decay in 
fluorescence signal to low levels, which is attributed to microgel degradation. DTT-
crosslinked microgels exhibited a small decrease in signal initially that stabilized and 
remained relatively constant for the duration of the observation period. Although we 
cannot rule out in vivo degradation of DTT-crosslinked microgels by collagenases or 
other mechanisms, the signal loss for these microgels could be related to release of 
unincorporated dye or oxidation of the fluorochrome. 
A key advantage of the 4-arm PEG-maleimide material is the ability to easily 
conjugate molecules presenting free thiols for efficient tethering of biomolecules within 
the microgel. We show that ~80% of fluorescent IgG or VEGF was maintained within the 
microgels in the absence of collagenase, with the remaining 20% of untethered proteins 
released within 4 hours. Importantly, the bioactivity of the VEGF tethered within the 
microgels remained similar to non-PEGylated VEGF. In vivo experiments also suggest 
VEGF remains bioactive over the course of the study. We posit that cell-controlled 
degradation of the microgels and sustained release of VEGF improves vascularization 
compared to materials that do not allow cellular based remodeling. Non-degradable 
microgels containing VEGF exhibited vascularization around the perimeter of the 
injection site, however, vessels were unable to penetrate within areas occupied by the 
microgels. Furthermore, without the sustained release of VEGF, vessels did not form 
even in the presence of a degradable microgel scaffold. 
 
 
 
5. Conclusion 
 
Synthetic microgels offer significant advantages as protein delivery vehicles, 
including minimally invasive, injectable delivery, control of protein release rates, control 
of particle size, and the ability to deliver multiple proteins with independently controllable 
release rates simultaneously. We demonstrate that protease-degradable microgels 
promote in vivo vascularization by controlled release of the vasculogenic protein VEGF 
and complete degradation of microgels that allows for tissue ingrowth and remodeling.  
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Figures 
 
 
 
 
Fig. 1: Generation of protease degradable microgels using flow focusing 
microfluidics (a) Image of microfludic flow focusing device with 200 µm nozzle. (b) 
Image of microgels generated using a 200 µm (left) or 50 µm (right) nozzle. (c) 
Coefficient of variation of diameter for microgels generated from 200 µm or 50 µm 
nozzles.  (d) Images of microgels crosslinked with DTT or VPM in the presence of 
collagenase or PBS. (e) Percent of DTT or VPM crosslinked microgels remaining after 
20 hour incubation with type 1 collagenase or PBS (n = 3 independent experiments). 
Significance compared to PBS control was determined using two-way ANOVA with 
Dunnett’s post-test, **p<0.01, ***p<0.005. 
  
 
 
 
Fig. 2: Controlled degradation of microgels and release of protein.  Release 
kinetics of fluorescent IgG from microgels crosslinked with different molar ratios of VPM 
to DTT. (a) Microgels were treated with type 1 collagenase (3.9 units/mL) or (b) PBS (n 
= 3 independent experiments). 
 
 
 
 
 
  
 
 
Fig. 3: Release kinetics and bioactivity of VEGF. Prior to formation into a gel, PEG-
4MAL was functionalized with fluorescently labeled VEGF (10 µg/mL). (a) 
Representative image of fluorescent VEGF bound within the microgels. (b) Percent of 
VEGF released over time in the presence of type 1 collagenase (3.9 units/mL) or PBS 
(n = 4 independent experiments). (c) Endothelial cell metabolic assay for soluble VEGF 
(100 ng/mL) or VEGF released from protease-degradable microgels treated with MMP-2 
(50 nM) and TIMP-1 (50nM) (n = 3 independent experiments). A total dose of 15 ng was 
used for both soluble and released VEGF conditions. 
 
 
  
  
 
 
Fig. 4: Protease degradable VEGF microgels promote vascularization in vivo. 
Microgels functionalized with a fluorescent RGD molecule were injected into the 
subcutaneous space on the back of C57BL/6 mice. (a) Images of microgel fluorescence 
at day 0 and day 14. (b) Percent of signal remaining over time compared to day 0. Data 
was fit with a simply decay model. (c) Representative fluorescent images of skin 
explants perfused with lectin to label vasculature. Fluorescent images of microgels in 
skin explants (bottom left). Dotted white line indicates the area represented in the large 
image. (d) Number of lectin labeled vessels per field of view (n = 4 mice per group). 
Significance was determined using one-way ANOVA with Tukey post-test, ***p<0.005. 
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Video S1. Generation of microgels using 200µm nozzle flow focusing device. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Video S2. Video of DTT crosslinked and VPM crosslinked microgels in the 
presence of protease. 
  
 
 
Fig. S1. Relationship between protease concentration and microgel degradation. 
VPM or DTT crosslinked microgels were incubated with collagenase at the indicated 
concentrations. The percent of microgels remaining was determined after 20 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S2. Kinetics of protein release from DTT and VPM microgels in the presence 
of protease. Kinetics of AF488-conjugated IgG or AF555-conjugated IgG released from 
microgels crosslinked with VPM or DTT, respectively. AF488- and AF55-conjugated 
microgels were mixed at a 1:1 ratio and then release of labeled IgG was measured in 
the presence of collagenase (3.9 units/mL) or PBS (n = 5 independent experiments). 
 
 
 
  
 
 
 
 
Fig. S3. VEGF maintains bioactivity following PEGylation. Endothelial cell 
proliferation assay to measure VEGF versus PEG-4MAL-VEGF bioactivity. Dashed line 
represents proliferation of cells treated with PEG-4MAL and dotted line represents cells 
treated with endothelial growth media-2 (EGM-2) (n = 4 independent experiments). 
 
 
 
 
 
 
 
